Composition and physicochemical properties of fasted-state human duodenal and jejunal fluid: A critical evaluation of the available data

Journal of Pharmaceutical Sciences

Volumn 103, Issue 11, 2014, Pages 3398-3411

  Fuchs, Alexander ^a   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Bile salts; Duodenum; Fasted state human intestinal fluid; Jejunum; pH; Phospholipids; Physicochemical characteristics; Solubility; Surface tension

Indexed keywords

BILE SALT; BUFFER; CHOLESTEROL; FATTY ACID; GLYCOCHENODEOXYCHOLIC ACID; GLYCOCHOLIC ACID; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; TAUROCHOLIC ACID; BILE ACID; SURFACTANT;

BIOCHEMICAL COMPOSITION; BODY FLUID; CONCENTRATION (PARAMETERS); DIET RESTRICTION; DUODENUM; DUODENUM FLUID; ENZYMATIC DEGRADATION; EVALUATION STUDY; HUMAN; HYDROXYLATION; IONIC STRENGTH; JEJUNUM; JEJUNUM FLUID; METHODOLOGY; NOTE; OSMOLARITY; PHYSICAL CHEMISTRY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SURFACE TENSION; CHEMISTRY; INTESTINAL SECRETIONS; PH; SECRETION (PROCESS);

BILE ACIDS AND SALTS; BUFFERS; DUODENUM; FASTING; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXYLATION; INTESTINAL SECRETIONS; JEJUNUM; OSMOLAR CONCENTRATION; PHOSPHOLIPIDS; SURFACE TENSION; SURFACE-ACTIVE AGENTS;

EID: 84915823458     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24183     Document Type: Note

References (89)

1. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12(3):413-420.
2. Brouwers J, Tack J, Lammert F, Augustijns P. 2006. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci 95(2):372-383.
3. Persson EM, Gustafsson AS, Carlsson AS, Nilsson RG, Knutson L, Forsell P, Hanisch G, Lennernas H, Abrahamsson B. 2005. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 22(12):2141-2151.
4. Persson EM, Nilsson RG, Hansson GI, Lofgren LJ, Liback F, Knutson L, Abrahamsson B, Lennernas H. 2006. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 23(4):742-751.
5. Porter CJ, Charman WN. 2001. In vitro assessment of oral lipid based formulations. Adv Drug Deliv Rev 50 Suppl 1:S127-147.
6. Porter CJ, Trevaskis NL, Charman WN. 2007. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6(3):231-248.
7. Dressman JB, Vertzoni M, Goumas K, Reppas C. 2007. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 59(7):591-602.
8. Annaert P, Brouwers J, Bijnens A, Lammert F, Tack J, Augustijns P. 2010. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur J Pharm Sci 39(1-3):15-22.
9. Bergman E, Forsell P, Tevell A, Persson EM, Hedeland M, Bondesson U, Knutson L, Lennernas H. 2006. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. Eur J Pharm Sci 29(3-4):205-214.
10. Bevernage J, Forier T, Brouwers J, Tack J, Annaert P, Augustijns P. 2011. Excipient-mediated supersaturation stabilization in human intestinal fluids. Mol Pharm 8(2):564-570.
11. Borde AS, Karlsson EM, Andersson K, Bjorhall K, Lennernas H, Abrahamsson B. 2012. Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids. Eur J Pharm Biopharm 80(3):630-637.
12. Clarysse S, Brouwers J, Tack J, Annaert P, Augustijns P. 2011. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids. Eur J Pharm Sci 43(4):260-269.
13. Clarysse S, Tack J, Lammert F, Duchateau G, Reppas C, Augustijns P. 2009. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 98(3):1177-1192.
14. Heikkila T, Karjalainen M, Ojala K, Partola K, Lammert F, Augustijns P, Urtti A, Yliperttula M, Peltonen L, Hirvonen J. 2011. Equilibrium drug solubility measurements in 96-well plates reveal similar drug solubilities in phosphate buffer pH 6.8 and human intestinal fluid. Int J Pharm 405(1-2):132-136.
15. Holmstock N, Bruyn TD, Bevernage J, Annaert P, Mols R, Tack J, Augustijns P. 2013. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. Eur J Pharm Sci 49(1):27-32.
16. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. 2006. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 23(1):165-176.
17. Lui CY, Amidon GL, Berardi RR, Fleisher D, Youngberg C, Dressman JB. 1986. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J Pharm Sci 75(3):271-274.
18. Perez de la Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J, Dressman J, Augustijns P. 2006. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 58(8):1079-1089.
19. Psachoulias D, Vertzoni M, Goumas K, Kalioras V, Beato S, Butler J, Reppas C. 2011. Precipitation in and supersaturation of contents of the upper small intestine after administration of two weak bases to fasted adults. Pharm Res 28(12):3145-3158.
20. Ulleberg EK, Comi I, Holm H, Herud EB, Jacobsen M, Vegarud GE. 2011. Human Gastrointestinal Juices Intended for Use in In Vitro Digestion Models. Food Dig 2(1-3):52-61.
21. Russell TL, Berardi RR, Barnett JL, Dermentzoglou LC, Jarvenpaa KM, Schmaltz SP, Dressman JB. 1993. Upper gastrointestinal pH in seventy-nine healthy, elderly, North American men and women. Pharm Res 10(2):187-196.
22. Bevernage J, Brouwers J, Clarysse S, Vertzoni M, Tack J, Annaert P, Augustijns P. 2010. Drug supersaturation in simulated and human intestinal fluids representing different nutritional states. J Pharm Sci 99(11):4525-4534.
23. Kalantzi L, Persson E, Polentarutti B, Abrahamsson B, Goumas K, Dressman JB, Reppas C. 2006. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 23(6):1373-1381.
24. Butler PJ, Mitchell AWM, Ellis H. 2012. Applied radiological anatomy. 2nd ed., Cambridge; New York: Cambridge University Press.
25. Bergman E, Forsell P, Persson EM, Knutson L, Dickinson P, Smith R, Swaisland H, Farmer MR, Cantarini MV, Lennernas H. 2007. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. Int J Pharm 341(1-2):134-142.
26. Brouwers J, Ingels F, Tack J, Augustijns P. 2005. Determination of intraluminal theophylline concentrations after oral intake of an immediate- and a slow-release dosage form. J Pharm Pharmacol 57(8):987-996.
27. Brouwers J, Tack J, Augustijns P. 2007. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm Res 24(10):1862-1869.
28. Brouwers J, Tack J, Augustijns P. 2007. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. Int J Pharm 336(2):302-309.
29. Fadda HM, Sousa T, Carlsson AS, Abrahamsson B, Williams JG, Kumar D, Basit AW. 2010. Drug solubility in luminal fluids from different regions of the small and large intestine of humans. Mol Pharm 7(5):1527-1532.
30. Lindahl A, Ungell AL, Knutson L, Lennernas H. 1997. Characterization of fluids from the stomach and proximal jejunum in men and women. Pharm Res 14(4):497-502.
31. Pedersen BL, Brondsted H, Lennernas H, Christensen FN, Mullertz A, Kristensen HG. 2000. Dissolution of hydrocortisone in human and simulated intestinal fluids. Pharm Res 17(2):183-189.
32. Pedersen BL, Mullertz A, Brondsted H, Kristensen HG. 2000. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res 17(7):891-894.
33. Knutson L, Odlind B, Hallgren R. 1989. A new technique for segmental jejunal perfusion in man. Am J Gastroenterol 84(10):1278-1284.
34. Lennernas H, Ahrenstedt O, Hallgren R, Knutson L, Ryde M, Paalzow LK. 1992. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm Res 9(10):1243-1251.
35. Carriere F, Renou C, Ransac S, Lopez V, De Caro J, Ferrato F, De Caro A, Fleury A, Sanwald-Ducray P, Lengsfeld H, Beglinger C, Hadvary P, Verger R, Laugier R. 2001. Inhibition of gastrointestinal lipolysis by Orlistat during digestion of test meals in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 281(1):G16-28.
36. Clarysse S, Psachoulias D, Brouwers J, Tack J, Annaert P, Duchateau G, Reppas C, Augustijns P. 2009. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 26(6):1456-1466.
37. Kostewicz ES, Carlsson AS, Hanisch G, Krumkühler K, Nilsson RG, Löfgren JL, Abrahamsson B. 2002. Comparison of dog and human intestinal fluid and its impact on solubility estimations. Eur J Pharm Sci 17(S111).
38. Ovesen L, Bendtsen F, Tage-Jensen U, Pedersen NT, Gram BR, Rune SJ. 1986. Intraluminal pH in the stomach, duodenum, and proximal jejunum in normal subjects and patients with exocrine pancreatic insufficiency. Gastroenterology 90(4):958-962.
39. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, Jarvenpaa KM. 1990. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm Res 7(7):756-761.
40. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. 1988. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut 29(8):1035-1041.
41. Rune SJ, Viskum K. 1969. Duodenal pH values in normal controls and in patients with duodenal ulcer. Gut 10(7):569-571.
42. Youngberg CA, Berardi RR, Howatt WF, Hyneck ML, Amidon GL, Meyer JH, Dressman JB. 1987. Comparison of gastrointestinal pH in cystic fibrosis and healthy subjects. Dig Dis Sci 32(5):472-480.
43. Aynaciyan AV, Bingham JR. 1969. pH of the duodenum of patients with and without duodenal ulcers measured with a radiotelemetering capsule. Gastroenterology 56(3):476-482.
44. Williamson JM, Russell RI, Goldberg A. 1969. A screening technique for the detection of achlorhydria using the Heidelberg capsule. Scand J Gastroenterol 4(4):369-375.
45. Yarbrough DR, 3rd, McAlhany JC, Weidner MG, Jr., Cooper N. 1969. Evaluation of the Heidelberg pH capsule. Method of tubeless gastric analysis. Am J Surg 117(2):185-192.
46. McNamara DP, Whitney KM, Goss SL. 2003. Use of a physiologic bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm Res 20(10):1641-1646.
47. Vertzoni M, Archontaki H, Reppas C. 2008. Determination of intralumenal individual bile acids by HPLC with charged aerosol detection. J Lipid Res 49(12):2690-2695.
48. Persson E, Lofgren L, Hansson G, Abrahamsson B, Lennernas H, Nilsson R. 2007. Simultaneous assessment of lipid classes and bile acids in human intestinal fluid by solid-phase extraction and HPLC methods. J Lipid Res 48(1):242-251.
49. Roda A, Cerre C, Simoni P, Polimeni C, Vaccari C, Pistillo A. 1992. Determination of free and amidated bile acids by high-performance liquid chromatography with evaporative light-scattering mass detection. J Lipid Res 33(9):1393-1402.
50. Scalia S. 1988. Simultaneous determination of free and conjugated bile acids in human gastric juice by high-performance liquid chromatography. J Chromatogr 431(2):259-269.
51. Scalia S, Pazzi P, Stabellini G, Guarneri M. 1988. HPLC assay of conjugated bile acids in gastric juice during ursodeoxycholic acid (Deursil) therapy of bile reflux gastritis. J Pharm Biomed Anal 6(6-8):911-917.
52. Gurantz D, Laker MF, Hofmann AF. 1981. Enzymatic measurement of choline-containing phospholipids in bile. J Lipid Res 22(2):373-376.
53. Armand M, Borel P, Pasquier B, Dubois C, Senft M, Andre M, Peyrot J, Salducci J, Lairon D. 1996. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol 271(1 Pt 1):G172-183.
54. Deferme S, Tack J, Lammert F, Augustijns P. 2003. P-glycoprotein attenuating effect of human intestinal fluid. Pharm Res 20(6):900-903.
55. McCloy RF, Greenberg GR, Baron JH. 1984. Duodenal pH in health and duodenal ulcer disease: effect of a meal, Coca-Cola, smoking, and cimetidine. Gut 25(4):386-392.
56. Bergstrom CA, Holm R, Jorgensen SA, Andersson SB, Artursson P, Beato S, Borde A, Box K, Brewster M, Dressman J, Feng KI, Halbert G, Kostewicz E, McAllister M, Muenster U, Thinnes J, Taylor R, Mullertz A. 2014. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Eur J Pharm Sci 57:173-199.
57. Kleberg K, Jacobsen J, Mullertz A. 2010. Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies. J Pharm Pharmacol 62(11):1656-1668.
58. Christiansen PM. 1968. The incidence of achlorhydria and hypochlorhydria in healthy subjects and patients with gastrointestinal diseases. Scand J Gastroenterol 3(5):497-508.
59. Holt PR, Rosenberg IH, Russell RM. 1989. Causes and consequences of hypochlorhydria in the elderly. Dig Dis Sci 34(6):933-937.
60. Segal HL, Shepardson CR, Plain GL. 1959. Gastric hydrochloric acid secretory response to orally administered betazole hydrochloride. N Engl J Med 261:542-544.
61. Varis K, Ihamaki T, Harkonen M, Samloff IM, Siurala M. 1979. Gastric morphology, function, and immunology in first-degree relatives of probands with pernicious anemia and controls. Scand J Gastroenterol 14(2):129-139.
62. Dermentzoglou LC. 1989. Changes in upper gastrointestinal pH with aging: Implications for drug Absorption. ed., Michigan: University of Michigan.
63. Morihara M, Aoyagi N, Kaniwa N, Kojima S, Ogata H. 2001. Assessment of gastric acidity of Japanese subjects over the last 15 years. Biol Pharm Bull 24(3):313-315.
64. Merfeld AE, Mlodozeniec AR, Cortese MA, Rhodes JB, Dressman JB, Admidon GL. 1986. The effect of pH and concentration on alpha-methyldopa absorption in man. J Pharm Pharmacol 38(11):815-822.
65. Kunze UR, Schwedt G. 2001. Grundlagen der qualitativen und quantitativen Analyse 25 Tabellen. 5 ed., Weinheim Wiley-VCH. p 47.
66. Martin AN, Leuenberger H. 2002. Physikalische Pharmazie pharmazeutisch angewandte physikalisch-chemische Grundlagen; mit 163 Tabellen. 4 ed., Stuttgart: Wissenschaftliche Verlags-Gesellschaft. p 385
67. Wiedmann TS, Liang W, Kamel L. 2002. Solubilization of drugs by physiological mixtures of bile salts. Pharm Res 19(8):1203-1208.
68. Williams HD, Trevaskis NL, Charman SA, Shanker RM, Charman WN, Pouton CW, Porter CJ. 2013. Strategies to address low drug solubility in discovery and development. Pharmacol Rev 65(1):315-499.
69. Hofmann AF. 1963. The Function of Bile Salts in Fat Absorption. The Solvent Properties of Dilute Micellar Solutions of Conjugated Bile Salts. Biochem J 89:57-68.
70. Holm R, Mullertz A, Mu H. 2013. Bile salts and their importance for drug absorption. Int J Pharm 453(1):44-55.
71. Porter CJ, Charman WN. 2001. Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50(1-2):61-80.
72. Kossena GA, Charman WN, Wilson CG, O'Mahony B, Lindsay B, Hempenstall JM, Davison CL, Crowley PJ, Porter CJ. 2007. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res 24(11):2084-2096.
73. Ladas SD, Isaacs PE, Murphy GM, Sladen GE. 1984. Comparison of the effects of medium and long chain triglyceride containing liquid meals on gall bladder and small intestinal function in normal man. Gut 25(4):405-411.
74. Tangerman A, van Schaik A, van der Hoek EW. 1986. Analysis of conjugated and unconjugated bile acids in serum and jejunal fluid of normal subjects. Clin Chim Acta 159(2):123-132.
75. Carey MC, Small DM. 1970. The characteristics of mixed micellar solutions with particular reference to bile. Am J Med 49:590-608.
76. Kossena GA, Charman WN, Boyd BJ, Dunstan DE, Porter CJ. 2004. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. J Pharm Sci 93(2):332-348.
77. Soderlind E, Karlsson E, Carlsson A, Kong R, Lenz A, Lindborg S, Sheng JJ. 2010. Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. Mol Pharm 7(5):1498-1507.
78. Hay DW, Cahalane MJ, Timofeyeva N, Carey MC. 1993. Molecular species of lecithins in human gallbladder bile. J Lipid Res 34(5):759-768.
79. Small D. 1986. The physical chemistry of lipids: from alkanes to phospholipids. Plenum Press: New York.
80. Arnesjo B, Nilsson A, Barrowman J, Borgstrom B. 1969. Intestinal digestion and absorption of cholesterol and lecithin in the human. Intubation studies with a fat-soluble reference substance. Scand J Gastroenterol 4(8):653-665.
81. Lind ML, Jacobsen J, Holm R, Mullertz A. 2007. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms. Eur J Pharm Sci 32(4-5):261-270.
82. Mansbach CM, 2nd, Cohen RS, Leff PB. 1975. Isolation and properties of the mixed lipid micelles present in intestinal content during fat digestion in man. J Clin Invest 56(4):781-791.
83. Robinson N. 1961. Lysolecithin. J Pharm Pharmacol 13:321-354.
84. Caspary WF. 1992. Physiology and pathophysiology of intestinal absorption. Am J Clin Nutr 55(1 Suppl):299S-308S.
85. Hildebrand A. 2002. Physikochemische Charakterisierung von Gallsalz-Mischmizellen als Grundlage für innovative Arzneistoffträgersysteme. Mathematisch-Naturwissenschaftlich-Technische Fakultät, ed., Halle: Martin-Luther-Universität Halle-Wittenberg. p 120.
86. Arndt M, Chokshi H, Tang K, Parrott NJ, Reppas C, Dressman JB. 2013. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state. Eur J Pharm Biopharm 84(3):633-641.
87. Fuchs A, Klöfer B, Leigh M, Dressman J. 2013. Evaluation of the Influence of Different Bile Salts and Phospholipids on the Surface Tension of Conventional Biorelevant Media. AAPS - Annual Meeting and Exposition, San Antonio, USA.
88. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. 1998. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 15(5):698-705.
89. Jantratid E, Janssen N, Reppas C, Dressman JB. 2008. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 25(7):1663-1676.